John Zuris. An Engineered AsCas12a Nuclease Facilitates the Rapid Generation of Therapeutic Cell Medicines. Presented at TIDES USA Oligonucleotide and Peptide Therapeutics, September 20-23, 2021.

Oct

3

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Aug

28

Editas Medicine to Participate in Upcoming Investor Conferences

Aug

7

Editas Medicine Announces Second Quarter 2024 Results and Business Updates